About the Authors
- Stina Wichert
-
* E-mail: stina.wichert@med.lu.se
Affiliation Department of Hematology, Skåne University Hospital and Lund University, Lund, Sweden
- Gunnar Juliusson
-
Affiliation Department of Hematology, Skåne University Hospital and Lund University, Lund, Sweden
- Åsa Johansson
-
Affiliation Clinical Immunology and Transfusion Medicine, University and Regional Laboratories Region Skåne, Lund, Sweden
- Elisabeth Sonesson
-
Affiliation Clinical Development, BioInvent International AB, Lund, Sweden
- Ingrid Teige
-
Affiliation Research, BioInvent International AB, Lund, Sweden
- Anna Teige Wickenberg
-
Affiliation Clinical Development, BioInvent International AB, Lund, Sweden
- Björn Frendeus
-
Affiliation Research, BioInvent International AB, Lund, Sweden
- Magnus Korsgren
-
Affiliation Clinical Development, BioInvent International AB, Lund, Sweden
- Markus Hansson
-
Affiliation Department of Hematology, Skåne University Hospital and Lund University, Lund, Sweden
Competing Interests
We have the following interests: ES, IT, ATW, BF, MK are, or were, full-time employees of BioInvent International AB at the time of this study. IT, ATW and BF are currently employed and own stock (>50,000) in the company. BF and MH are inventors on patents relating to BI-505 and anti-ICAM antibody therapy. These declarations do not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceptualization: BF MK MH. Data curation: SW ATW MH. Formal analysis: SW MH. Funding acquisition: BF MK. Investigation: SW GJ ÅJ ES. Methodology: SW ÅJ ES IT BF MK MH. Project administration: ES MK SW MH. Supervision: BF MK MH. Visualization: SW. Writing – original draft: SW. Writing – review & editing: SW GJ ÅJ ES IT ATW BF MK MH.